问题 › 我们无法判断战略是否有效 › 医疗服务提供商
无法出错的战略也就无法检验，而多数基于价值的合同战略正是这样写成的。 医疗服务提供商面临更难的结构性问题：已在38,000人身上承担了下行风险，却缺少定价所需的单次发作成本数据。任何可信的方案都必须同时掌握单次发作成本和 payer mix，而这两项数据通常分散在不同系统里，正是内部分析停滞的地方。
无法出错的战略也就无法检验，而多数基于价值的合同战略正是这样写成的。 医疗服务提供商面临更难的结构性问题：已在38,000人身上承担了下行风险，却缺少定价所需的单次发作成本数据。任何可信的方案都必须同时掌握单次发作成本和 payer mix，而这两项数据通常分散在不同系统里，正是内部分析停滞的地方。
战略无法评估的常见原因是它从未以可能在单次发作成本上失败的形式写明。增加基于价值合同的归属人数，不会产生任何与之相悖的观察，因此无论38,000人的实际结果如何，这个做法都能无限延续。
可检验的战略会写明机制——对 panel size 或 payer mix 采取这一行动，将在这一日期前带来单次发作成本的这一变化——并写明什么观察会证明机制失效。后半部分正是让 CFO 或医务主任能够据此管理的部分。
另一个常见原因是滞后。基于归属人数的战略周期长于报告周期，诚实的做法是提前找出领先指标，并预先说明每个提供商的贡献或单次发作成本应该达到什么水平。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 合同审查中缺少单次发作成本，尽管已对归属人数承担下行风险。
✓ 报告只列已完成的活动，如合同签署或 panel 扩大，却不说明与发作成本变化的关联。
✓ CFO 和医务主任对基于价值的合同是否有效得出不同结论，却没有共享数据来解决分歧。
通常会让情况更糟的做法。 增加更多关于归属人数和 panel size 的报告，只会增加数字量，却无法让战略在单次发作成本上变得可证伪。
It is for you if you run or finance a healthcare provider and the strategy has no failure condition written anywhere. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家医疗服务提供商. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Customer Value Architecture · sample company profile
The move. Turn $6.8 M downside-risk liability into a $22–35 M licensing platform within 36 months.
The leak it closes. Eliminates $6.8 M downside exposure by enabling proactive utilization management.
The assumption it rests on. Cost-measurement platform achieves <5 % variance versus manual abstraction within 12 months — the engine put the probability at 0.75.
| Investment required | $2.1–3.5 M over 36 months |
| Expected return | 6.3–16.7× cash-on-cash within 36 months based on $196 M current revenue base. |
| Revenue, year 1 | $0 licensing revenue; $1.8 M internal cost avoidance |
| Revenue, year 2 | $4.2 M licensing ARR (40 physicians × $120K + 5 external practices × $400K) |
| Revenue, year 3 | $13.5 M licensing ARR (90 physicians × $120K + 18 external practices × $400K) plus $4–8 M shared-savings upside |
| Exit criteria | Terminate platform investment if variance exceeds 8 % by Month 18 OR if fewer than 40 physicians sign licensing agreements by Month 24; redeploy remaining capital to ASC surgeon-retention track. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Proprietary EFF Methodology, one of 29 engagements the platform runs. For 医疗服务提供商 it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
测量它所依赖的机制，而不是它承诺的结果。结果滞后，机制提前变动，能更快告诉你因果主张是否成立。
在开始前就决定，并与机制的自然周期绑定。事后决定只会让时间表去配合已出现的结果。
这通常说明战略不够具体，无法形成清晰检验。把它缩小，直到一个数字就能解决争议为止。
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית